Search Results
Baxter Publishes its First Sustainability Accounting Standards Board (SASB) Index and Celebrates Continued Inclusion in the Dow Jones Sustainability Indices (DJSI)
Baxter International Inc. (NYSE:BAX), a leading global medical products company, today published its first Sustainability Accounting Standards Board (SASB) index, a voluntary public disclosure that provides transparent and relevant corporate responsibility information to investors and other key stakeholders.
Baxter Declares Quarterly Dividend
Baxter International Inc. (NYSE:BAX), a leading global medical products company, today announced that its Board of Directors has declared a quarterly cash dividend of $0.245 per share of common stock. The dividend is payable on January 4, 2021, to shareholders of record as of December 4, 2020. The indicated annual dividend rate is $0.98 per share of common stock. About Baxter
Baxter Reports Third-Quarter 2020 Results
Baxter International Inc. (NYSE:BAX), a leading global medical products company, today reported earnings for the third quarter of 2020 and updated its outlook for full-year 2020.
Baxter Announces Proposed $650 Million Senior Notes Offering
Baxter International Inc. (NYSE:BAX), a leading global medical products company, today announced that it proposes to offer, subject to market conditions and other factors, $650 million aggregate principal amount of senior notes due 2031 (the “Notes”).
Baxter Issues Urgent Device Correction to Reinforce Important Safety Information Regarding Cleaning Practices of All Sigma Spectrum Infusion Pumps (V6, V8, and IQ)
Baxter International Inc. announced today it has issued an Urgent Device Correction to reinforce important safety information regarding cleaning practices of all Spectrum infusion pumps distributed in the United States, Canada, and the Caribbean, as deviations from the specified cleaning methods may impair infusion pump functionality and performance.
Baxter Supports New Study Showing Blood Purification with Oxiris Filter Set Can Play a Role in the Management of Severely Ill COVID-19 Patients
Baxter International Inc. (NYSE:BAX), a global leader in acute care, recognizes the findings of a prospective, multicenter, observational study on data from the OxirisNet Registry evaluating severely ill patients with COVID-19 in Italy treated with extracorporeal (outside the body) blood purification (EBP) using the company’s Oxiris filter set.
Baxter to Present at 29th Annual Credit Suisse Virtual Healthcare Conferencce
Baxter International Inc. (NYSE:BAX), a leading global medical products company, will present at the 29th Annual Credit Suisse Virtual Healthcare Conference via webcast on Monday, November 9, 2020. Jay Saccaro, Baxter's chief financial officer, is scheduled to present at 11:45 a.m. Eastern Time. The live webcast of Baxter's presentation can be accessed at www.baxter.com and will be available for replay through November 9, 2021.
Baxter Announces U.S. FDA Approval of Clinimix and Clinimix E with Higher Protein for Patients Requiring Parenteral Nutrition
A global leader in clinical nutrition, today announced the U.S. Food and Drug Administration (FDA) approval of new formulations of Clinimix (amino acids in dextrose) Injections and Clinimix E (amino acids with electrolytes in dextrose and calcium) Injections.
Baxter Announces Support for Finalization of Core Component of the Advancing American Kidney Health Initiative
Baxter International Inc. (NYSE:BAX), a leading global medical products company, today issued this statement: